The Hazard Ratio Trap: Why the FDA Just Pulled the Plug on Summit’s $29 Dream

(SeaPRwire) –   The FDA threw a cold wrench into Summit Therapeutics’ high-flying narrative. The agency rejected the application for ivonescimab, demanding survival data that the current trial could not statistically deliver. This clash between strict standards and eager markets triggered a brutal plunge. Summit stock dropped nearly seventeen percent in premarket trading, landing near eleven dollars and seventy cents. Investors are now facing a harsh reality. Progression-free survival is no longer enough to satisfy regulators. The anxiety is palpable across the biotech sector. How many promising therapies will survive this rigorous gauntlet? The market is demanding concrete answers.

The FDA sent a Complete Response Letter on Sunday. The agency rejected ivonescimab paired with platinum-containing chemotherapy. This combo targets advanced lung cancer patients after EGFR TKI failure. The Phase 3 HARMONi trial hit its progression-free survival endpoint. However, the overall survival results fell short of statistical significance. A follow-up analysis showed a hazard ratio of 0.76. This positive trend held across Asian and Western cohorts. The safety profile remained manageable with no new signals. Jefferies views this rejection as the base case for investors. They see limited downside in the stock. Barclays trimmed its price target to eighteen dollars. Summit’s partner, Akeso, flagged the stock volatility. China approved the drug last May, but Western markets remain untapped.

The commercial loop for Summit remains tied to its partner, Akeso. Without Western regulatory approval, the US market remains completely closed. This leaves the firm dependent on future data to unlock value. The next major catalyst is the HARMONi-3 squamous survival data. Investors will watch that readout closely in late 2026. The broader industry lesson is clear. Surrogate endpoints like progression-free survival no longer guarantee market approval. Companies must design trials with overall survival as the primary goal. For investors, the practical advice is simple. Discount assets relying on proxy metrics in regulated Western markets. Focus capital on firms with mature survival data.